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Abstract
BACKGROUND: Several parathyroid scintigraphy protocols have been used for preoperative localization of hyperfunctioning 
parathyroid glands in patients with hyperparathyroidism. The aim of this study is to compare the diagnostic accuracy of vari-
ous parathyroid scintigraphy protocols.
MATERIAL AND METHODS: A retrospective diagnostic accuracy study with histopathology as the reference standard was done. 
Five imaging protocols were investigated including planar dual tracer Tc-99m pertechnetate/Tc-99m sestamibi (DT), planar dual 
phase Tc-99m sestamibi (DP), and combined dual tracer dual phase (DTDP) protocols, as well as add-on single photon emis-
sion computed tomography (SPECT), and single photon emission computed tomography/computed tomography (SPECT/CT).
RESULTS: A total of 63 patients underwent parathyroid scintigraphy and subsequent parathyroid surgery with a total of 106 
excised lesions with histopathological diagnosis. On a lesion-based analysis, sensitivity and specificity (with 95% confidence 
interval) of protocols were as follows. DT protocol: 69.4% (53.1–82.0%) and 80.0% (49.0–94.3%); DP protocol: 78.6% (52.4–92.4%) 
and 33.3% (9.7–70.0%); DTDP protocol: 64.7% (47.9–78.5%) and 50.0% (18.8–81.2%); SPECT: 92.3% (66.7–98.6%) and 75.0% 
(30.1–95.4%); SPECT/CT: 80.0% (49.0–94.3%) and 75.0% (30.1–95.4%). All protocols had perfect sensitivity for detection of 
parathyroid adenoma whereas SPECT was the most sensitive method for detection of hyperplastic parathyroid glands.
CONCLUSION: Planar parathyroid scintigraphy using the DT protocol has a trend towards being more accurate than DP and 
DTDP protocols. Additional imaging with SPECT and SPECT/CT had a trend towards being more accurate than planar imaging.
KEY words: radionuclide imaging; parathyroid scintigraphy; SPECT; SPECT/CT; parathyroid glands; 
hyperparathyroidism
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Background
Hyperparathyroidism is characterized by excessive parathy-
roid hormone secretion by parathyroid glands. The incidence of 
primary hyperparathyroidism ranges from 34 to 120 per 100,000 in 
women and 13 to 36 per 100,000 in men [1] and may be caused 
by parathyroid adenoma, hyperplasia, or rarely, parathyroid carci-
noma [2]. Secondary and tertiary hyperparathyroidism are mostly 
found in patients with chronic kidney disease with prevalence 
inversely proportional to renal function [3]. Sequala of chronic 
hyperparathyroidism include bone loss and symptoms related 
to hypercalcemia as well as increased risk of cardiac death [4]. 
Management includes medical treatment and surgical removal of 
hyperfunctioning parathyroid glands. Preoperative localization of 
hyperfunctioning parathyroid glands can be done by various im-
aging modalities including ultrasound [5–8], magnetic resonance 
imaging [5, 9, 10], and computed tomography [5]. However, the 
modality most utilized is nuclear medicine isotopic imaging using 
various radiopharmaceuticals. Although newer positron emission 
tomography radiopharmaceuticals including C-11 methionine 
[11, 12], and F-18 fluorocholine [13, 14] have been investigated, 
the mainstay of radionuclide imaging in hyperparathyroidism 
relies on Tc-99m sestamibi which localizes in hyperfunctioning 
parathyroid glands. Several imaging protocols have been used. 
Planar imaging can be done using the dual tracer (DT) protocol 
where the image using Tc-99m sestamibi which localizes in both 
the thyroid and hyperfunctioning parathyroid lesions is compared 
with an image using Tc-99m pertechnetate or I-123 sodium iodide 
which localizes solely in the thyroid. The dual phase (DP) protocol 
compares two or more Tc-99m sestamibi images obtained at 
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different time points and diagnosis is based on the observation that 
Tc-99m sestamibi washes out of the thyroid more rapidly than from 
hyperfunctioning parathyroid lesions [15]. Tomographic imaging 
including single photon emission computed tomography (SPECT) 
and single photon emission computed tomography/computed 
tomography (SPECT/CT) has been suggested to provide improved 
diagnostic accuracy over planar imaging [16–19]. The purpose of 
this study was to determine the diagnostic accuracy of various nu-
clear medicine parathyroid imaging techniques for preoperative 
localization of hyperfunctioning parathyroid glands.
Materials and methods
This single center, retrospective, diagnostic accuracy study 
was approved by the authors’ institutional review board (reference 
no. HE581328). Inclusion criteria were 1) patients diagnosed with 
hyperparathyroidism who 2) underwent preoperative parathyroid 
scintigraphy, and 3) have histopathological diagnosis of surgically 
excised lesions. Patients who underwent previous neck surgery 
were excluded. 
Parathyroid scintigraphy
Several parathyroid scintigraphy protocols are done at the au-
thors’ center. Planar imaging was done using either Vertex V60 EPIC 
HP dual headed gamma camera (ADAC, CA, USA), Genesys single 
headed gamma camera (ADAC, CA, USA), or Discovery NM/CT 670 
(GE Healthcare, IL, USA) equipped with low energy high-resolution 
collimator with a 128 × 128 imaging matrix with an energy peak 
set at 140 keV ± 10%. Patients were examined using one of the 
following protocols.
Dual tracer protocol (DT)
The patient was first intravenously injected with 130 MBq of 
Tc-99m pertechnetate and anterior static planar image of the neck 
and chest was obtained 20 minutes later. Then the patient was in-
jected with 555 MBq of Tc-99m sestamibi, and without changing 
patient position another static planar image was obtained 15 min-
utes later. 
Dual phase protocol (DP)
After the patient was injected with 555 MBq of Tc-99m sestamibi, 
an early static planar image of the neck and chest was obtained 
at 15 minutes. Delayed image at 60 minutes was later obtained. In 
some patients, further delayed images were obtained at 120 minu-
tes and/or 180 minutes depending on the discretion of the nuclear 
medicine physician on duty that day.
Combined dual tracer dual phase protocol (DTDP)
This is a continuation of the DT protocol. In some instances, 
after reviewing the initial planar Tc-99m pertechnetate and Tc-99m 
sestamibi images, the nuclear medicine may deem that the initial 
images were not yet sufficient for diagnosis and may order an ad-
ditional set of delayed planar Tc-99m sestamibi image to possibly 
provide additional information. 
SPECT and SPECT/CT
SPECT or SPECT/CT were done in some patients in addition to 
planar imaging, up to the discretion of the nuclear medicine physician 
on duty. The timing of SPECT or SPECT acquisition varied from 
15 minutes to 120 minutes after Tc-99m sestamibi injection. SPECT 
and SPECT/CT may be done regardless of the initial planar protocol 
the patient underwent. SPECT was acquired using a 128 × 128 
imaging matrix in step-and-shoot mode (25 seconds/shoot, 6 de-
grees/step). For SPECT/CT, the non-contrast CT portion of the 
study was done using 120 kV, 80 mA, and 2.5 mm slice thickness.
Image interpretation
All images were independently interpreted by two experienced 
nuclear medicine physicians blinded to clinical information. A third 
nuclear medicine physician resolved any discrepant readings. 
Readings included positivity of the scan, number, and location of 
the focal uptake (right upper, right lower, left upper, and left lower). 
For the DT protocol, Tc-99m pertechnetate and Tc-99m sestamibi 
images were visually assessed side by side, as well as by using 
parathyroid subtraction software included in the Xeleris 3 software 
suite provided by the vendor (GE Healthcare, IL, USA). For the DP 
protocol, early and delayed Tc-99m sestamibi images were visually 
assessed side by side. For the DTDP protocol, all available im-
ages including the Tc-99m pertechnetate, early Tc-99m sestamibi, 
subtracted image, and delayed Tc-99m sestamibi images were 
interpreted side by side. In patients who had additional SPECT and 
SPECT/CT examination, the SPECT and SPECT/CT images were 
interpreted separately after interpretation of the planar images. 
Reference standard
Histopathological examination was used as the reference stand-
ard. Positive lesions include parathyroid adenoma, parathyroid 
hyperplasia, and parathyroid carcinoma. All other histopathological 
readings were considered negative. The location of lesions noted 
in pathological reports was compared with location of focal uptake 
in parathyroid scintigraphy.
Statistical analysis
Patient demographics and characteristics of histopathological 
findings were presented using descriptive statistics. Diagnostic 
performance was derived from 2 × 2 contingency tables of read-
ings from each scintigraphic protocol in relation to the reference 
standard. Analysis was done on a “per lesion” basis. Shapiro-Wilk 
test was used to test for distribution normality of continuous vari-
ables. Two-sample t-test was used to compare the size of true 
positive glands and false negative glands across different scinti-
graphic protocols. A p value of < 0.05 indicates statistical signifi-
cance. Accompanying 95% confidence intervals (95% C.I.) were 
reported appropriate. Confidence intervals for diagnostic accuracy 
indices were estimated using Wilson’s score interval estimation for 
binomial proportions.
Results
From 1 May 2006 to 31 May 2015, 290 patients were sent 
for parathyroid scintigraphy at the authors’ center. Among these, 
63 patients underwent parathyroidectomy with a total of 106 ex-
cised lesions having final histopathological diagnosis that could 
be compared with parathyroid scintigraphy. Patient characteris-
tics are described in Table 1. The cohort had an average age of 
48.2 years with almost equal male to female ratio. Over half of 
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was 1.8 ± 0.8 cm. Across different imaging protocols, overall, true 
positive lesions had a trend towards being larger than false negative 
ones. Only in the DP technique were truly positive lesions signifi-
cantly larger than falsely negative ones. Table 4 provides details of 
size comparison between true positive and false negative lesions.
When comparing between detection rates of various scin-
tigraphic protocols for detection of parathyroid adenoma and 
parathyroid hyperplasia, all imaging protocols had 100% detec-
tion rate for parathyroid adenoma. All three planar protocols had 
similar sensitivity for detection of hyperplastic parathyroid 
glands with the DP protocol being the most sensitive. Add-on 
SPECT imaging improved the detection rate for parathyroid 
hyperplasia to 90%, but SPECT/CT provided a more modest im-
provement to 77.8%. Details of sensitivity of different scintigraphic 
protocols for detection of parathyroid adenoma and hyperplasia 
are provided in Table 5.
Discussion
In this study, diagnostic accuracy of different parathyroid 
scintigraphy protocols was investigated using histopathological 
diagnosis as the reference standard. The cohort consisted mostly 
of patients with underlying end-stage renal disease, thus explain-
ing the dominance of parathyroid hyperplasia as the cause of 
hyperparathyroidism. The DP protocol had higher sensitivity than 
the DT and DTDP protocols. This finding is contrary to most pre-
vious studies that reported that dual tracer had higher sensitivity 
than single tracer protocols [20–27]. The discrepant finding in the 
current study could, to some degree, be due to context bias since 
most of the patients sent for parathyroid scintigraphy at the 
authors’ center have end-stage renal disease with pronounced 
hyperparathyroidism. It is conceivable that readers are more likely 
to interpret the findings as anomalies — irregularities in radiotracer 
uptake in the Tc-99m sestamibi image could have been interpreted 
as positive because the DP protocol relies only on the Tc-99m 
sestamibi without Tc-99m pertechnetate images outlining the 
thyroid for comparison. This is reflected in the specificity of the DP 
protocol which was the poorest among all protocols. When taking 
both sensitivity and specificity into account, the DT protocol had 
the highest accuracy with the DTDP protocol having the poorest 
accuracy, a finding which is not in line with a previous study which 
demonstrated that combined dual tracer and dual phase imaging 
Table 1. Patient characteristics
Characteristic
Number 63 (100%)
Age (years, mean ± SD) 48.2 ± 13.8
Sex
Male 30 (47.6%)
Female 33 (52.4%)
Type of hyperparathyroidism
Primary 19 (30.2%)
Secondary 5 (7.9%)
Tertiary 27 (42.9%)
Undetermined 12 (19.0%)
Underlying end-stage renal disease
Yes 33 (52.4%)
No 18 (28.6%)
Undetermined 12 (19.0%)
Time from scintigraphy to surgery (days)
Median (IQR) 65 (45–114)
Range 2–596
Parathyroid scintigraphy protocol
Dual tracer 24 (38.1%)
Dual phase 18 (28.6%)
Combined dual tracer dual phase 21 (33.3%)
Additional SPECT or SPECT/CT
No 48 (76.2%)
SPECT 15 (23.8%)
SPECT/CT 7 (11.1%)
Table 2. Histopathological diagnosis of 106 surgically excised lesions
Histopathological diagnosis Number Percent
Parathyroid hyperplasia 69 65.1%
Parathyroid adenoma 13 12.3%
Parathyroid carcinoma 2 1.9%
Normal parathyroid gland 13 12.3%
Normal thyroid tissue 4 3.8%
Lymph node 3 2.8%
Other 2 1.9%
All 106 100.0%
patients had underlying end-stage renal disease and were clinically 
diagnosed with secondary or tertiary hyperparathyroidism.
As shown in Table 2, of the 106 excised lesions, 79.2% were 
positive, with most of the lesions being parathyroid hyperplasia. 
Parathyroid adenomas accounted for about one-eighth of le-
sions and two parathyroid carcinomas were found. The most com-
mon negative histology was normal parathyroid glands. 
Among the 63 patients, 24 patients underwent scintigraphy with 
the DT protocol and had 46 excised lesions that could be compared 
with histopathological results, 18 patients were examined with the 
DP protocol with 20 excised lesions, and 21 patients underwent 
the DTDP protocol with 40 excised lesions. The DP protocol had 
the highest sensitivity but poorest specificity while the DT protocol 
was most accurate for localizing parathyroid lesions. The DTDP 
protocol yielded the lowest accuracy. In addition to planar imag-
ing, SPECT was also done in 15 patients with a total of 17 excised 
lesions while SPECT/CT was additionally done in 7 patients with 14 
excised lesions. SPECT had a higher sensitivity of 92.3% compared 
with SPECT which was 80.0% sensitive, while both modalities had 
equal specificity of 75%. However, confidence intervals of all imag-
ing protocols overlapped, thus superiority of a single protocol over 
others could not be concluded. A summary of diagnostic perfor-
mance of the imaging protocols are provided in Table 3.
From the 106 excised lesions, 70 parathyroid lesions had 
pathological report regarding lesion size. The average diameter 
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provided better accuracy than either dual tracer or dual phase 
alone [25]. This could be because patients who underwent DTDP 
imaging were patients who initially underwent DT imaging and find-
ings from the initial Tc-99m sestamibi and Tc-99m pertechnetate 
images were deemed insufficient for diagnosis by the nuclear medi-
cine physician on duty thus prompting further delayed imaging, so 
patients in the DTDP group represented ‘difficult’ patients which 
findings were likely to be inconclusive to begin with. Both add-on 
SPECT and SPECT/CT improved the diagnostic accuracy over 
planar imaging alone which concurs with previous studies [5, 
16–19, 28]. However, SPECT imaging appeared to have a higher 
diagnostic accuracy than SPECT/CT which is unexpected and 
contradicts a previous study which demonstrated the superiority 
of SPECT/CT over SPECT alone [29]. This could be because the 
previous study used diagnostic quality CT as opposed to low-dose 
CT as was used in the current study, or could be due to chance 
Table 3. Diagnostic performance of planar parathyroid scintigraphy protocols, SPECT and SPECT/CT
Dual tracer Dual phase Combined dual tracer 
dual phase
Add–on SPECT Add–on SPECT/CT
Value 95% C.I. Value 95% C.I. Value 95% C.I. Value 95% C.I. Value 95% C.I.
Patients 24 18 21 15 7
Excised lesions 46 20 40 17 14
True positive 25 11 22 12 8
False positive 2 4 3 1 1
False negative 11 3 12 1 2
True negative 8 2 3 3 3
Sensitivity 69.4% 53.1–82.0% 78.6% 52.4–92.4% 64.7% 47.9–78.5% 92.3% 66.7–98.6% 80.0% 49.0–94.3%
Specificity 80.0% 49.0–94.3% 33.3% 9.7–70.0% 50.0% 18.8–81.2% 75.0% 30.1–95.4% 75.0% 30.1–95.4%
Accuracy 71.7% 57.5–82.7% 65.0% 43.3–81.9% 62.5% 47.0–75.8% 88.2% 65.7–96.7% 78.6% 52.4–92.4%
Positive 
predictive value
92.6% 76.6–97.9% 73.3% 48.0–89.1% 88.0% 70.0–95.8% 92.3% 66.7–98.6% 88.9% 56.5–98.0%
Negative 
predictive value
42.1% 23.1–63.7% 40.0% 11.8–76.9% 20.0% 7.0–45.2% 75.0% 30.1–95.4% 60.0% 23.1–88.2%
Likelihood ratio 
positive
3.47 1.55–7.79 1.18 0.96–1.44 1.29 0.90–1.85 3.69 0.84–16.26 3.20 0.70–14.62
Likelihood ratio 
negative
0.38 0.32–0.45 0.64 0.20–2.06 0.71 0.46–1.09 0.10 0.01–0.74 0.27 0.10–0.69
Table 4. Comparison of size between true positive and false negative lesions
Protocol* True positive False negative P-value
Number of lesions** Lesion size (cm.) Number of lesions** Lesion size (cm.)
Mean S.D. Mean S.D.
DT 23 1.7 0.85 10 1.3 0.71 0.0723
DP 10 2.6 0.96 3 1.2 0.91 0.0241
DTDP 17 1.8 0.57 7 1.7 0.37 0.3327
Add-on SPECT 10 2.2 0.63 1 2.0 — —
Add-on SPECT/CT 7 2.2 0.75 1 2.0 — —
*DT — dual tracer protocol; DP — dual phase protocol; DTDP — dual tracer dual phase protocol
**The size of some excised lesions was not mentioned in the histopathological report
Table 5. Sensitivity of different parathyroid scintigraphy protocols for detection of parathyroid adenoma and hyperplasia
Protocol Parathyroid adenoma Parathyroid hyperplasia
TP* FN** Sensitivity 95% C.I. TP* FN** Sensitivity 95% C.I.
DT 3 0 100.0% 43.8–100.0% 21 11 65.6% 48.3–79.6%
DP 5 0 100.0% 56.6–100.0% 6 3 66.7% 35.4–87.9%
DTDP 5 0 100.0% 56.6–100.0% 17 11 60.7% 42.4–76.4%
Add-on SPECT 3 0 100.0% 43.8–100.0% 9 1 90.0% 59.6–98.2%
Add-on SPECT/CT 1 0 100.0% 20.7–100.0% 7 2 77.8% 45.3–93.7%
*TP — true positive 
**FN — false negative
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given the small number of patients who underwent SPECT and 
SPECT/CT in this study. 
Regarding the effect of lesion size on detection of parathyroid 
lesions, overall, larger lesions were more likely to be detected 
than smaller lesions, a finding which is in agreement with previ-
ous studies [29–31]. All imaging protocols had perfect sensitivity 
for detection of parathyroid adenomas but had reduced sensitivity 
for parathyroid hyperplasia, a finding supported by previous stu-
dies [8, 9, 18, 20, 25] and is likely because adenomas tend to be 
larger and have higher degree of Tc-99m sestamibi uptake than 
hyperplastic glands. 
Limitations of the study include the retrospective design and 
the relatively small sample size in each scintigraphic protocol. 
Comparison of diagnostic accuracy between different proto-
cols therefore represents only trends as demonstrated by the 
overlapping confidence intervals among all imaging protocols. 
Analysis of scintigraphic results in relation to laboratory data such 
as parathyroid hormone level could not be done, since laboratory 
data could not be recovered in about one-third of cases. Com-
parison of scintigraphic findings could be done only in relation to 
lesion diameter since lesion weight was not routinely documented 
at the authors’ center.
In conclusion, for planar scintigraphy, the dual tracer protocol 
seemed to provide the highest accuracy for localization of hy-
perfunctioning parathyroid lesions in a cohort predominated by 
end-stage renal disease patients. SPECT and SPECT/CT improved 
diagnostic accuracy although superiority of SPECT/CT over SPECT 
alone could not be demonstrated. 
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